sarpogrelate has been researched along with Arteriosclerosis Obliterans in 6 studies
sarpogrelate: structure given in first source
Arteriosclerosis Obliterans: Common occlusive arterial disease which is caused by ATHEROSCLEROSIS. It is characterized by lesions in the innermost layer (ARTERIAL INTIMA) of arteries including the AORTA and its branches to the extremities. Risk factors include smoking, HYPERLIPIDEMIA, and HYPERTENSION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Forty patients who had diabetes with nephropathy and arteriosclerosis obliterans and had already been treated with angiotensin II receptor blocker (n = 40) were randomly assigned to sarpogrelate (300 mg/d; n = 20) or aspirin group (100 mg/d; n = 20)." | 9.13 | Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes. ( Ishizuka, T; Ito, S; Mori, T; Nako, K; Ogawa, S, 2008) |
| "To evaluate the effects of the 5-HT2 receptor antagonist sarpogrelate hydrochloride (sarpogrelate) on platelet responses in arteriosclerosis obliterans (ASO), we examined platelet aggregation and its relationships to platelet-derived growth factor (PDGF), soluble P-selectin (sP-selectin), and transforming growth factor-beta 1 (TGF-beta1)." | 9.09 | Effects of sarpogrelate hydrochloride on adenosine diphosphate- or collagen-induced platelet responses in arteriosclerosis obliterans. ( Kariyazono, H; Masuda, H; Nakamura, K; Sakata, R; Yamada, K, 2001) |
| "Sarpogrelate has a therapeutic effect on patients with atherosclerotic obliterans." | 6.78 | Prospective study of sarpogrelate hydrochloride on patients with arteriosclerosis obliterans. ( Liu, J; Liu, P; Qian, S; Ren, S; Wang, W, 2013) |
| "The aim was to evaluate the significance of arteriosclerosis obliterans-related biomarkers in patients with type 2 diabetes mellitus (T2DM), and to compare the effects of sarpogrelate, eicosapentaenoic acid (EPA) and pitavastatin on these markers." | 5.27 | Effects of sarpogrelate, eicosapentaenoic acid and pitavastatin on arterioslcerosis obliterans-related biomarkers in patients with type 2 diabetes (SAREPITASO study). ( Ito, T; Nomura, S; Okuda, Y; Omoto, S; Shouzu, A; Suzuki, M; Taniura, T, 2018) |
| "Forty patients who had diabetes with nephropathy and arteriosclerosis obliterans and had already been treated with angiotensin II receptor blocker (n = 40) were randomly assigned to sarpogrelate (300 mg/d; n = 20) or aspirin group (100 mg/d; n = 20)." | 5.13 | Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes. ( Ishizuka, T; Ito, S; Mori, T; Nako, K; Ogawa, S, 2008) |
| "To evaluate the effects of the 5-HT2 receptor antagonist sarpogrelate hydrochloride (sarpogrelate) on platelet responses in arteriosclerosis obliterans (ASO), we examined platelet aggregation and its relationships to platelet-derived growth factor (PDGF), soluble P-selectin (sP-selectin), and transforming growth factor-beta 1 (TGF-beta1)." | 5.09 | Effects of sarpogrelate hydrochloride on adenosine diphosphate- or collagen-induced platelet responses in arteriosclerosis obliterans. ( Kariyazono, H; Masuda, H; Nakamura, K; Sakata, R; Yamada, K, 2001) |
| "Sarpogrelate has a therapeutic effect on patients with atherosclerotic obliterans." | 2.78 | Prospective study of sarpogrelate hydrochloride on patients with arteriosclerosis obliterans. ( Liu, J; Liu, P; Qian, S; Ren, S; Wang, W, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nomura, S | 1 |
| Taniura, T | 1 |
| Shouzu, A | 1 |
| Omoto, S | 1 |
| Suzuki, M | 1 |
| Okuda, Y | 1 |
| Ito, T | 1 |
| Higashi, Y | 1 |
| Fujita, M | 1 |
| Origasa, H | 1 |
| Miyata, T | 1 |
| Matsuo, H | 1 |
| Naritomi, H | 1 |
| Shigematsu, H | 1 |
| Ren, S | 1 |
| Qian, S | 1 |
| Wang, W | 1 |
| Liu, J | 1 |
| Liu, P | 1 |
| Yamakawa, J | 1 |
| Takahashi, T | 1 |
| Itoh, T | 1 |
| Kusaka, K | 1 |
| Kawaura, K | 1 |
| Wang, XQ | 1 |
| Kanda, T | 1 |
| Ogawa, S | 1 |
| Mori, T | 1 |
| Nako, K | 1 |
| Ishizuka, T | 1 |
| Ito, S | 1 |
| Nakamura, K | 1 |
| Kariyazono, H | 1 |
| Masuda, H | 1 |
| Sakata, R | 1 |
| Yamada, K | 1 |
5 trials available for sarpogrelate and Arteriosclerosis Obliterans
| Article | Year |
|---|---|
Effects of sarpogrelate, eicosapentaenoic acid and pitavastatin on arterioslcerosis obliterans-related biomarkers in patients with type 2 diabetes (SAREPITASO study).
Topics: Adiponectin; Aged; Aged, 80 and over; Ankle Brachial Index; Arteriosclerosis Obliterans; Biomarkers; | 2018 |
Prospective study of sarpogrelate hydrochloride on patients with arteriosclerosis obliterans.
Topics: Aged; Ankle Brachial Index; Arteriosclerosis Obliterans; Cardiovascular Agents; Chi-Square Distribut | 2013 |
A novel serotonin blocker, sarpogrelate, increases circulating adiponectin levels in diabetic patients with arteriosclerosis obliterans.
Topics: Adiponectin; Aged; Arteriosclerosis Obliterans; Diabetes Mellitus, Type 2; Female; Humans; Intercell | 2003 |
Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Arteriosclerosis Obliterans; Aspirin; Ch | 2008 |
Effects of sarpogrelate hydrochloride on adenosine diphosphate- or collagen-induced platelet responses in arteriosclerosis obliterans.
Topics: Adenosine Diphosphate; Aged; Arteriosclerosis Obliterans; Case-Control Studies; Collagen; Female; Hu | 2001 |
1 other study available for sarpogrelate and Arteriosclerosis Obliterans
| Article | Year |
|---|---|
Study design of SEASON registry: prospective Surveillance of cardiovascular Events in an Antiplatelet-treated arterioSclerosis Obliterans patients in JapaN )SEASON).
Topics: Arteriosclerosis Obliterans; Cardiovascular Diseases; Humans; Japan; Platelet Aggregation Inhibitors | 2010 |